S 6422: Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

  
  STATE OF NEW YORK ________________________________________________________________________ 6422 2025-2026 Regular Sessions  IN SENATE March 13, 2025 ___________ Introduced by Sen. HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education AN ACT to amend the education law and the public health law, in relation to prescription labels for mifepristone, misoprostol, gonadotropin-re- leasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the 2 education law, as added by chapter 7 of the laws of 2025, is amended to 3 read as follows: 4 b-1. Notwithstanding paragraph b of this section, the prescription 5 label for mifepristone, misoprostol, [and their generic alternatives] 6 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic 7 steroids, alpha reductase inhibitors, progestins, or drug classes for 8 hormone replacement therapy for treatment of gender dysphoria, may 9 include the name or address of the dispensing health care practice 10 instead of the name of the dispenser. 11 § 2. Subdivision 1-a of section 6810 of the education law, as added by 12 chapter 7 of the laws of 2025, is amended to read as follows: 13 1-a. Notwithstanding subdivision one of this section, at the 14 prescriber's request, the prescription label for mifepristone, misopros- 15 tol, [and their generic alternatives] gonadotropin-releasing hormone 16 agonists, pubertal suppressants, anabolic steroids, alpha reductase 17 inhibitors, progestins, or drug classes for hormone replacement therapy 18 for treatment of gender dysphoria, may include the name of the prescrib- 19 ing health care practice instead of the name of the prescriber. 20 § 3. The public health law is amended by adding a new section 280-d to 21 read as follows: EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD10852-01-5 
 S. 6422 2 1 § 280-d. Patient notification of prescription label change. A health 2 care prescriber shall inform the patient if such prescriber has included 3 or has requested to include the name or address of the prescribing 4 health care practice instead of the name of such prescriber on the 5 prescription label when prescribing mifepristone, misoprostol, gonado- 6 tropin-releasing hormone agonists, pubertal suppressants, anabolic ster- 7 oids, alpha reductase inhibitors, progestins, or drug classes for 8 hormone replacement therapy for treatment of gender dysphoria. 9 § 4. This act shall take effect immediately.